
2027 Future Talent Program - Payer & Health Systems Oncology - Intern
Merck
Summary
The Future Talent Program features internships that last up to 12 weeks and will include one or more projects. The Payer and Health Systems (PHS) team is seeking a motivated and collaborative 2027 summer intern for a 10-12 week internship to support strategic initiatives focused on oncology, patient access, health systems, and medical affairs.
Job description
Primary Responsibilities
- Support development and refinement of health system and payer insight-gathering priorities.
- Analyze and summarize stakeholder insights and identify trends across the oncology landscape.
- Evaluate payer policy, reimbursement, quality, pathway, and regulatory developments affecting oncology care.
- Contribute to field engagement planning resources and internal training materials.
- Collaborate with cross-functional Medical Affairs stakeholders.
- Develop and present findings for project assignments with recommendations to PHS leadership.
Learning Objectives
- Understand the role of U.S. Medical Affairs payer and health system access team within the pharmaceutical industry.
- Gain exposure to payer and health-system decision-making in oncology.
- Learn how stakeholder insights inform medical strategy.
- Strengthen analytical, communication, and project management skills.
Requirements
- Currently pursuing a PharmD, MD, DNP, or other doctoral-level clinical or health sciences degree and returning to school following the internship
- Strong verbal and written communication skills
- Strong organizational and project management skills
- Ability to manage multiple priorities and meet deadlines
- Ability to work collaboratively in cross-functional teams
- Proficiency with Microsoft Office applications
Company overview
Merck & Co., Inc., known as Merck in the United States and Canada and MSD (Merck Sharp & Dohme) internationally, is a premier American multinational pharmaceutical company headquartered in Rahway, New Jersey. Founded in 1891 as the U.S. subsidiary of the German Merck Group, the company became independent following World War I and has since grown into one of the world's largest biomedical companies, ranking fourth globally by revenue. Merck operates across three core business segments: pharmaceuticals, vaccines, and animal health products. The company is renowned for its groundbreaking research and development, having brought numerous life-saving medicines to market including Keytruda (pembrolizumab), a leading immunotherapy for cancer treatment that generated $29.5 billion in 2024 revenue, and Gardasil, a revolutionary HPV vaccine. With approximately 75,000 employees worldwide, Merck maintains a robust pipeline of innovative therapies focused on oncology, vaccines, hospital acute care, cardiology, neuroscience, virology, immunology, and diabetes. The company invests heavily in R&D, spending $17.9 billion in 2024 alone, demonstrating its commitment to advancing scientific discovery. Merck's legacy spans over 130 years of bringing hope to humanity through important medicines and vaccines, operating with a purpose to use leading-edge science to save and improve lives globally while fostering an inclusive workforce and responsible business practices.